The Department of Veterans Affairs (VA) announced Thursday it will conduct a clinical trial to evaluate the effectiveness of semaglutide, an injectable GLP-1 drug, in treating alcohol abuse. This initiative aims to address a persistent issue within the military and veteran community, where excessive drinking has historically been a concern.
The study plans to enroll over 600 veterans across 18 VA medical centers. Participants will receive weekly injections of either a GLP-1 drug or a placebo for 28 weeks. Researchers will monitor changes in alcohol consumption, overall health, and quality of life to assess the drug's potential as a new treatment option.
Excessive alcohol consumption is a complex problem affecting veterans differently, with some estimates indicating that 14% of veterans abuse alcohol, compared to just under 10% of the general population. VA research suggests that males and those who served in combat zones are at a higher risk of developing alcohol use disorders. A 2020 study also indicated that veterans with traumatic brain injuries may be more prone to excessive drinking.
GLP-1 drugs are known to potentially dampen cravings, and early research suggests they may offer short-term benefits for alcoholism and other substance abuse issues. However, the full extent of their effectiveness, safety, and long-term effects for addiction treatment is still under investigation and requires further research.